Health Highlights: Feb. 18, 2019

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Immunotherapies Prove Their Mettle Against Kidney Cancer Adding immunotherapy to targeted cancer therapy boosted survival for kidney cancer...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news

Related Links:

AbstractImmunotherapy has become the fourth cancer therapy after surgery, chemotherapy, and radiotherapy. In particular, immune checkpoint inhibitors are proved to be unprecedentedly in increasing the overall survival rates of patients with refractory cancers, such as advanced melanoma, non-small cell lung cancer, and renal cell carcinoma. However, inhibitor therapies are only effective in a small proportion of patients with problems, such as side effects and high costs. Therefore, doctors urgently need reliable predictive biomarkers for checkpoint inhibitor therapies to choose the optimal therapies. Here, we review the bi...
Source: Frontiers of Medicine - Category: General Medicine Source Type: research
We present a comprehensive knowledge of immune therapy through PD-1/PD-L1 blockade that argues how efficient the process is, in colon cancer carcinoma. In this review, we discuss the responsiveness of immunotherapy on PD-1/PD-L1 blockade and various tactics for overcoming weak responses to these checkpoint inhibitors in CRC. More research using controlled trials is required to enable new discoveries to provide continued success with immune-based therapies and grounds for optimism about the future of CRC patients.Graphical abstractThe mechanism of interaction between PD-1+ T-cells and PD-L1/2+ tumor cells.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
We present a comprehensive knowledge of immune therapy through PD-1/PD-L1 blockade that argues how efficient the process is, in colon cancer carcinoma. In this review, we discuss the responsiveness of immunotherapy on PD-1/PD-L1 blockade and various tactics for overcoming weak responses to these checkpoint inhibitors in CRC. More research using controlled trials is required to enable new discoveries to provide continued success with immune-based therapies and grounds for optimism about the future of CRC patients. PMID: 30522017 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
Publication date: February 2019Source: Biomedical Signal Processing and Control, Volume 48Author(s): Francisco F. Teles, João M. LemosAbstractDuring the last years several clinical decision support systems have been developed, some of which clearly improved the results obtained with standard clinical practice. However, this kind of decision computing process has not been quite explored in cancer treatment. In this work a control system that designs an optimal therapy based on adaptive control methods, aiming to allow the eradication of a metastatic renal cell carcinoma as quickly and efficiently as possible, and wit...
Source: Biomedical Signal Processing and Control - Category: Biomedical Science Source Type: research
ConclusionsThis case series represents the first description of potential skeletal adverse effects related to immune checkpoint inhibitors. These findings are important for providers caring for patients who experience musculoskeletal symptoms and may merit additional evaluation.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Conclusions: Early favorable signs of FDG-PET parameters may vary among diseases with immune checkpoint inhibitors. Mean FDG uptake was elevated in several immune-related organs at the early restaging scan. Among them, elevated FDG accumulation in thyroid might be a candidate sign of monitoring effectiveness of immunotherapy observed earlier than immune-related lymphadenopathy. Relationship between % change () of PET parameters and patients outcome% chage (Î") of PET parametersMalignant melanoma(Odds, 95%CI, p)Malignant lymphoma (Odds, 95%CI, p)Renal cell carcinoma (Odds, 95%CI, p)Î&quo...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Other Solid Tumors Source Type: research
Abstract As a treatment for solid tumors, dendritic cell (DC)-based immunotherapy has not been as effective as expected. Here, we review the reasons underlying the limitations of DC-based immunotherapy for solid tumors and ask what can be done to improve immune cell-based cancer therapies. Several reports show that, rather than a lack of immune induction, the limited efficacy of DC-based immunotherapy in cases of renal cell carcinoma (RCC) likely results from inhibition of immune responses by tumor-secreted TGF-β and an increase in the number of regulatory T (Treg) cells in and around the solid tumor. Indeed,...
Source: Translational Oncology - Category: Cancer & Oncology Authors: Tags: Transl Oncol Source Type: research
SummaryImmunotherapies comprise of a  class of cancer therapies that are increasingly used for treatment of several cancer entities. Active immunotherapies encompassing immune checkpoint inhibitors are the most widespread class of immunotherapies, with indications for melanoma, non-small lung cancer, renal cell carcinoma, urothelial c arcinoma, head and neck squamous cell carcinoma, and Hodgkin’s lymphoma. Immune checkpoint inhibitors have demonstrated unique response patterns that are not adequately captured by traditional response criteria such das the Response Evaluation Criteria in Solid Tumors (RECIST) and ...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
Summary Nivolumab belongs to the standard therapy in the second‐line setting of metastatic renal cell carcinoma (mRCC). Although deep and long‐lasting responses are seen in some patients, the majority of patients will further progress. PD‐L1 as predictive biomarker is still under critical evaluation. Thus, more accurate biomarkers are clearly warranted. Here, we investigated for the first time the predictive role of IDO‐1, a negative immune‐regulatory molecule, on clear cell RCC tissues of 15 patients undergoing nivolumab therapy. IDO‐1 and other immune inhibitory molecules (PD‐L1, PD‐L2, FOXP3) as well as ...
Source: Cancer Science - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
Conclusion This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. We don't know what the conditions that required antibiotic treatment were and whether these could have affected the response to immunotherapy. We don't know whether the antibiotics themselves influenced how well the immunotherapy worked, or whether it was their effect on gut bacteria. We also don't know whether having high levels of part...
Source: NHS News Feed - Category: Consumer Health News Tags: Cancer Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Therapy | General Medicine | Immunotherapy | Kidney Cancer | Urology & Nephrology